Trial Profile
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs MT 3724 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Molecular Templates
- 18 Aug 2022 The number of treatment arms increased from 8 to 9. New primary endpoints added, trial focus TU, PK, PD and AR.
- 30 Aug 2021 Status changed from active, no longer recruiting to discontinued (Sponsor decision following clinical hold).
- 12 Nov 2020 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.